Spotlight On: Humira® (Adalimumab) / Amjevita™ (Adalimumab-Atto) / Cyltezo® (Adalimumab-Adbm) / Hyrimoz™ (Adalimumab-Adaz) / Hadlima™ (Adalimumab-Bwwd) / Abrilada™ (Adalimumab-Afzb) / Hulio® (Adalimumab-Fkjp) / Yusimry™ (Adalimumab-Aqvh) / Idacio® (Adalimumab-Aacf) / Yuflyma® (Adalimumab-Aaty) / Simlandi® (Adalimumab-Ryvk) - April 2026

Why It Matters

The way claims are counted amplifies the perceived pressure on adalimumab’s patent estate, potentially hastening biosimilar entry and reshaping pricing dynamics in the $30 billion global biologics market.

Key Takeaways

• Multiple IPRs target overlapping adalimumab patent claims
• Claims counted per proceeding, leading to double-counting across cases
• Over 10 biosimilar names listed for adalimumab in 2026
• Litigation claim counts limited to one per lawsuit per patent
• Patent challenges could accelerate biosimilar market entry

Pulse Analysis

Adalimumab remains one of the most litigated biologics, with AbbVie’s Humira® defending a dense web of patents that span composition‑of‑matter, formulation, and method‑of‑use claims. Recent Inter‑Partes Review (IPR) filings—grouped as 2017‑00826/01008 and 2017‑00827/01009—target overlapping claim sets, meaning a single patent can be contested in multiple proceedings. This counting methodology inflates the total number of challenged claims, signaling to the market that the patent barrier is under intense scrutiny. Legal analysts watch these metrics closely, as they often foreshadow the timing of biosimilar launches.

For biosimilar developers, the proliferation of claim challenges presents both risk and opportunity. Companies such as Amgen (Amjevita™) and Boehringer Ingelheim (Cyltezo™) have already secured FDA approval, but their commercial roll‑out depends on clearing the patent thicket. When courts or the Patent Trial and Appeal Board invalidate key claims, biosimilars can enter at lower prices, compressing Humira’s market share, which still commands roughly 30 % of global biologics sales. Conversely, successful claim defenses can extend exclusivity, preserving premium pricing and revenue streams for the originator.

Strategically, patent owners are now balancing aggressive defense with settlement negotiations to avoid protracted litigation costs. The detailed claim‑counting rules outlined in the report help counsel prioritize which patents to defend vigorously and which to abandon or license. As the IPR landscape evolves, stakeholders—investors, payors, and providers—must monitor not just the number of lawsuits, but the specific claim categories under attack, because they dictate the speed at which cost‑saving biosimilars may reach patients. This nuanced view of adalimumab’s patent challenges offers a clearer forecast of market dynamics over the next few years.